These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 1331230)

  • 1. Paroxetine: a pharmacological review.
    Johnson AM
    Int Clin Psychopharmacol; 1992 Jun; 6 Suppl 4():15-24. PubMed ID: 1331230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacologic profile of paroxetine, a new selective serotonin reuptake inhibitor.
    Tulloch IF; Johnson AM
    J Clin Psychiatry; 1992 Feb; 53 Suppl():7-12. PubMed ID: 1531829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paroxetine: an overview of the efficacy and safety of a new selective serotonin reuptake inhibitor in the treatment of depression.
    Nemeroff CB
    J Clin Psychopharmacol; 1993 Dec; 13(6 Suppl 2):10S-17S. PubMed ID: 8106649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Paroxetine: pharmacokinetics and pharmacodynamics].
    Hiemke C
    Fortschr Neurol Psychiatr; 1994 Sep; 62 Suppl 1():2-8. PubMed ID: 7959522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of the selective serotonin reuptake inhibitors.
    DeVane CL
    J Clin Psychiatry; 1992 Feb; 53 Suppl():13-20. PubMed ID: 1531816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Central serotonin receptors and chronic treatment with selective serotonin reuptake inhibitors in the rat: comparative effects of fluoxetine and paroxetine].
    Le Poul E; Lima L; Laporte AM; Even C; Doucet E; Fattaccini CM; Laaris N; Hamon M; Lanfumey L
    Encephale; 1995; 21(2):123-32. PubMed ID: 7781583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety profile of paroxetine.
    Boyer WF; Blumhardt CL
    J Clin Psychiatry; 1992 Feb; 53 Suppl():61-6. PubMed ID: 1531828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paroxetine: a new serotonin reuptake inhibitor for the treatment of depression.
    Sherman TL; McDougle CJ; Price LH
    Conn Med; 1993 Sep; 57(9):587-92. PubMed ID: 8252846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An overview of paroxetine.
    Boyer WF; Feighner JP
    J Clin Psychiatry; 1992 Feb; 53 Suppl():3-6. PubMed ID: 1531819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Introductory comments: a brief history of the development of paroxetine.
    Braestrup C
    Int Clin Psychopharmacol; 1992 Jun; 6 Suppl 4():1-3. PubMed ID: 1431006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flesinoxan challenge suggests that chronic treatment with paroxetine in rats does not desensitize receptors controlling 5-HT synthesis.
    Skelin I; Yamane F; Diksic M
    Neurochem Int; 2008 Dec; 53(6-8):236-43. PubMed ID: 18786747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical effects of serotonin reuptake inhibitors in the treatment of depressive illness.
    Burrows GD; McIntyre IM; Judd FK; Norman TR
    J Clin Psychiatry; 1988 Aug; 49 Suppl():18-22. PubMed ID: 3045107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor.
    Nemeroff CB
    Pharmacotherapy; 1994; 14(2):127-38. PubMed ID: 8197030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuation and maintenance treatments in major depression: the neglected role of monoamine oxidase inhibitors.
    Kennedy SH
    J Psychiatry Neurosci; 1997 Mar; 22(2):127-31. PubMed ID: 9074307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversible monoamine oxidase-A inhibitors in resistant major depression.
    Nolen WA; Hoencamp E; Bouvy PF; Haffmans PM
    Clin Neuropharmacol; 1993; 16 Suppl 2():S69-76. PubMed ID: 8313400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind comparison of paroxetine, imipramine, and placebo in major depression.
    Shrivastava RK; Shrivastava SH; Overweg N; Blumhardt CL
    J Clin Psychiatry; 1992 Feb; 53 Suppl():48-51. PubMed ID: 1531825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress in the psychopharmacology of antidepressants: selective uptake and MAO-inhibitors.
    Delini-Stula A
    Schweiz Arch Neurol Psychiatr (1985); 1986; 137(5):121-33. PubMed ID: 2431464
    [No Abstract]   [Full Text] [Related]  

  • 18. Serotonin uptake inhibition by the monoamine oxidase inhibitor brofaromine.
    Waldmeier PC; Graf T; Germer M; Feldtrauer JJ; Howald H
    Biol Psychiatry; 1993 Mar; 33(5):373-9. PubMed ID: 8471696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paroxetine. A review of its pharmacology, therapeutic use in depression and therapeutic potential in diabetic neuropathy.
    Holliday SM; Plosker GL
    Drugs Aging; 1993; 3(3):278-99. PubMed ID: 8324301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-Based Design of Highly Selective and Potent G Protein-Coupled Receptor Kinase 2 Inhibitors Based on Paroxetine.
    Waldschmidt HV; Homan KT; Cato MC; Cruz-Rodríguez O; Cannavo A; Wilson MW; Song J; Cheung JY; Koch WJ; Tesmer JJ; Larsen SD
    J Med Chem; 2017 Apr; 60(7):3052-3069. PubMed ID: 28323425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.